STAT Plus Data on Amgens KRASblocking cancer drug are encouraging but also raise new questions
STAT Plus: Data on Amgen’s KRAS-blocking cancer drug are encouraging, but also raise new questions
03:45 EDT 8 Sep 2019 |
STAT
Amgen says its KRAS-targeted cancer drug is showing broad ability to attack tumors.
More From BioPortfolio on "STAT Plus: Data on Amgen’s KRAS-blocking cancer drug are encouraging, but also raise new questions"